Inhibrx Biosciences, Inc.(INBX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Inhibrx Biosciences, Inc. (INBX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INBX at 30.0/100 on a 32-signal composite quality model, placing it at rank #2,506 of 2,961 stocks — the bottom half of the AI-ranked universe. INBX scores in the top quartile across revenue growth (95.7), institutional flow (90.4). Areas of concern include free cash flow (0.4) and revenue scale (0.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Inhibrx Biosciences, Inc. reports net income of $-36.6M, free cash flow of $-29.9M. Top institutional holders of INBX by reported 13-F value include MORGAN STANLEY, PERCEPTIVE ADVISORS, Sanofi, based on the most recent SEC filings. INBX trades on the Nasdaq exchange and files with the SEC under CIK 2007919. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INBX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inhibrx Biosciences, Inc. directly from SEC EDGAR.